This information was published on 2026-07-28T13:42:19 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2532098 (IR 1845424) |
| (220) |
18 Dec 2024
|
| (300) |
EM, 09 Aug 2024, 019065956
|
| (500) |
It is a condition of registration that any use in respect of pharmaceuticals will be limited to such goods containing substances belonging to the pharmacological group designated by the International Non-Proprietary Name stem IO-
It is a condition of protection that any use in respect of pharmaceuticals will be limited to such goods containing substances belonging to the pharmacological group designated by the International Non Proprietary Name stem IO- The applicant has advised that the words in the Mark have no meaning in English |
| (511) (510) |
Class 1
Chemical preparations for scientific and industrial purposes; genetically engineered polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular artificial polypeptides and proteins and nucleic acid coding for these; diagnostic preparations, except for medical or veterinary use. Class 5 Pharmaceuticals, medical and veterinary preparations; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of illnesses, ailments and/or disorders in humans and/or animals, in particular bone, sensory organ, viral, urinary tract, kidney, metabolic or central nervous system diseases, complaints and/or disorders and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medicinal health preparations for use in the treatment or prevention of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the treatment or prevention of complications associated with such diseases, ailments and/or disorders; pharmaceutical preparations and formulations and medical health preparations, in particular artificial polypeptides and proteins, in particular antibodies and antibody-like polypeptides and proteins, and nucleic acid coding for these, in particular for use in the following areas: treatment or prevention of various types of cancer, inflammatory diseases and autoimmune diseases; diagnostic preparations and biomarker reagents for medical or veterinary purposes; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular circulatory, respiratory, endocrine, neurological, cardiovascular, nutritional, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of human and/or animal diseases, ailments and/or disorders, in particular bone, sensory organ, virus, urinary tract, kidney, metabolic or central nervous system diseases, ailments and/or disorders and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders; diagnostic preparations and diagnostic biomarker reagents for the diagnosis and/or prognosis of diseases, ailments and/or disorders in humans and/or animals, in particular infectious, autoimmune or immunological, cell proliferative and/or oncological diseases, ailments and/or disorders, cancers, tumours and metastases and the diagnosis and/or prognosis in relation to complications associated with such diseases, ailments and/or disorders. Class 42 Scientific services and research relating thereto; scientific services and research relating to biology, chemistry or medicine, as well as immunology, oncology, molecular biology, cell biology, biochemistry and/or medicinal chemistry, and relating to the discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic agents and diagnostic biomarker reagents and/or diagnostic apparatus; conducting evaluations in the field of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of platform technology, namely a cancer immunotherapy platform for the production of therapeutics; chemical, biological and biochemical laboratory services; conducting chemical, biochemical and biological analyses; cancer diagnostics for scientific purposes; services of a biological or biochemical laboratory; biological and biochemical examination services; providing technical and scientific information about a biotechnology company, its technologies, projects, product-candidates, products and/or services via a web site on a global computer network; software design and development; design and development of computer software for use in the fields of biology, chemistry or medicine, in particular immunology, oncology, molecular biology, cellular biology, biochemistry and/or medicinal chemistry, as well as in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents and/or diagnostic apparatus. |
| (540) | IOMX |
| (550) | Word |
| (730) |
iOmx Therapeutics AG
|
| (750) |
Cooper IP Pty Ltd
|
Find out more about publications on the About page.